| Dr Kristen Elizabeth Heck, OD | |
|
41301 Us Highway 280, Sylacauga, AL 35150-8046 | |
| (256) 245-4104 | |
| (256) 245-8668 |
| Full Name | Dr Kristen Elizabeth Heck |
|---|---|
| Gender | Female |
| Speciality | Optometry |
| Experience | 20 Years |
| Location | 41301 Us Highway 280, Sylacauga, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003918921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT.0003515 (Colorado) | Secondary |
| 152W00000X | Optometrist | S-A82-TA-661 (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Abba Eye Care Pc | 1355231051 | 19 |
News Archive
InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
Researchers at the University of Jyväskylä highlight how the struggles caused by the COVID-19 pandemic can guide us towards an equitable use of our shared environment and a transition towards sustainability.
› Verified 2 days ago
| Provider Name | Abba Eye Care Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1952301129 PECOS PAC ID: 1355231051 Enrollment ID: O20040317000504 |
News Archive
InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
Researchers at the University of Jyväskylä highlight how the struggles caused by the COVID-19 pandemic can guide us towards an equitable use of our shared environment and a transition towards sustainability.
› Verified 2 days ago
| Provider Name | Colorado Vision |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1669932679 PECOS PAC ID: 3971837832 Enrollment ID: O20190626001714 |
News Archive
InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
Researchers at the University of Jyväskylä highlight how the struggles caused by the COVID-19 pandemic can guide us towards an equitable use of our shared environment and a transition towards sustainability.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kristen Elizabeth Heck, OD 320 E Fontanero St, Ste 201, Colorado Springs, CO 80907-7525 Ph: (719) 599-2020 | Dr Kristen Elizabeth Heck, OD 41301 Us Highway 280, Sylacauga, AL 35150-8046 Ph: (256) 245-4104 |
News Archive
InSite Vision Incorporated today announced that patient enrollment has been completed in the DOUBle Phase 3 clinical trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) for the treatment of blepharitis.
Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).
Sanofi-aventis announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine (rDNA) injection) compared to twice-daily insulin detemir. The study was presented during the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Vienna.
Researchers at the University of Jyväskylä highlight how the struggles caused by the COVID-19 pandemic can guide us towards an equitable use of our shared environment and a transition towards sustainability.
› Verified 2 days ago
Family Eye Care Of Sylacauga Llc Optometrist Medicare: Medicare Enrolled Practice Location: 493 W 3rd St, Sylacauga, AL 35150 Phone: 256-245-7696 | |
Dr. Stacy Leeann Cantley, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 493 W 3rd St, Sylacauga, AL 35150 Phone: 256-245-7696 Fax: 256-245-6693 | |
Family Eye Care Optometrist Medicare: Not Enrolled in Medicare Practice Location: 493 W 3rd St, Sylacauga, AL 35150 Phone: 256-245-7696 Fax: 256-245-6693 | |
Norton Avenue Eye Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 301 S Norton Ave, Sylacauga, AL 35150 Phone: 256-207-1277 Fax: 256-891-7855 | |
Sylacauga Eye Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6 N Elm Ave, Sylacauga, AL 35150 Phone: 256-369-2838 | |
Thomas M Kines, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 493 W 3rd Street, Sylacauga, AL 35150 Phone: 256-245-7696 Fax: 256-245-6693 |